TC
SMMT icon

Truvestments Capital’s Summit Therapeutics SMMT Stock Holding History

Truvestments Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36K Sell
2,470
-133
-5% -$2.36K 0.01% 597
2026
Q1 		$49.4K Hold
2,603
– – 0.01% 500
2025
Q4 		$45.5K Buy
2,603
+1,736
+200% +$32.7K 0.01% 470
2025
Q3 		$17.9K Buy
867
+239
+38% +$5.8K ﹤0.01% 617
2025
Q2 		$13.4K Buy
+628
New +$14.3K ﹤0.01% 610

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Truvestments Capital's SMMT Position: Q2 2026 in Review

Truvestments Capital reduced its Summit Therapeutics (SMMT) stake by 5.1% in Q2 2026, selling an estimated $2.36K and leaving 2,470 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #597.

Truvestments Capital first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $49.4K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Truvestments Capital held 2,470 shares of Summit Therapeutics worth $36K as of Q2 2026.
  • Truvestments Capital sold 133 Summit Therapeutics shares in Q2 2026, an estimated $2.36K.
  • Summit Therapeutics made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #597 holding.
  • Truvestments Capital first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Truvestments Capital's Summit Therapeutics position peaked at $49.4K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.